HIV and accelerated atheroprogression: Role of antiretroviral therapy

Current Pharmaceutical Biotechnology

Volumn 13, Issue 1, 2012, Pages 88-96

  Di Biagio, Antonio ^a   Del Bono, Valerio ^a   Rosso, Raffaella ^a   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

AIDS; Antiretroviral therapy; Atherosclerosis; Cardiovascular risk; Endothelium; HIV infection; Lipids

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHRONIC INFLAMMATION; DIABETES MELLITUS; DISEASE COURSE; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DYSLIPIDEMIA; ENDOTHELIUM INJURY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFECTION; INSULIN RESISTANCE; PATHOGENESIS; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; RISK FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84855827248     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112798868520     Document Type: Article

References (66)

1. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults http://www.cdc.gov/mmwr/ preview/ mmwrhtml/ 00018871.htm (Accessed, May 1, 2010).
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescent GL.pdf (Accessed May 1, 2010).
3. Egger, M.;, May, M.; Chêne, G.; Phillips, A.N.; Ledergerber, B.; Dabis, F.; Costagliola, D.; D'Arminio Monforte, A.; de Wolf, F.; Reiss, P.; Lundgren, J.D.; Justice, A.C.; Staszewski, S.; Leport, C.; Hogg, R.S.; Sabin, C.A.; Gill, M.J.; Salzberger, B.; Sterne, J.A. ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, 2002, 360(9327), 119-129.
4. Sackoff, J.E.; Hanna, D.B.; Pfeiffer, M.R.; Torian, L.V. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann. Intern. Med., 2006, 145, 397-406
5. Lohs E N.; Hansen, E.; Gerstoft, J.; Obel, N. Improved survival in HIV-infected persons: consequences and perspectives. J. Antimicrob. Chemother., 2007, 60, 461-463.
6. Lewden, C.; Salmon, D.; Morlat, P.; Bévilacqua, S.; Jougla, E.; Bonnet, F.; Héripret, L.; Costagliola, D.; May, T.; Chêne, G. Mortality 2000 study group. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int. J. Epidemiol., 2005, 34, 121-130.
7. Kaplan, R.C.; Kingsley, L.A.; Sharrett, A.R.; Li, X.; Lazar, J.; Tien, P.C.; Mack, W.J.; Cohen, M.H.; Jacobson, L.; Gange, S.J. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin. Infect. Dis., 2007, 45, 1074-1081.
8. May, M.; Sterne, J.A.; Shipley, M.; Brunner, E.; d'Agostino, R.; Whincup, P.; Ben-Shlomo, Y.; Carr, A.; Ledergerber, B.; Lundgren, J.D.; Phillips, A.N.; Massaro, J.; Egger, M. A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int. J. Epidemiol., 2007, 36, 1309-1318.
9. Vittecoq, D.; Escaut, L.; Chironi, G.; Teicher, E.; Monsuez, J.J.; Andrejak, M.; Simon, A. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS., 2003, 17, S70-S76.
10. Carr, A. Cardiovascular risk factors in HIV-infected patients. J. Acquir. Immune. Defic. Syndr., 2003, 34 Suppl., S73-78.
11. Hsue, P.Y.; Waters, D.D. What a cardiologist needs to know about patients with human immunodeficiency virus infection. Circulation, 2005, 112, 3947-3957.
12. Hansson, G.K. Atherosclerosis: an immune disease: the Anitschkov Lecture 2007. Atherosclerosis, 2009, 202, 2-10.
13. Hansson, G. K; Libby, P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol., 2006, 6, 508-519.
14. Hazenberg, M.D.; Stuart, J.W.; Otto, S.A.; Borleffs, J.C.; Boucher, C. A,; De Boer, R.J.; Miedema, F.; Hamann, D. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in Patients before and during highly active antiretroviral therapy. Blood, 2000, 95, 249-255.
15. Valdez, H.; Connick, E.; Smith, K.Y.; Lederman, M.M.; Bosch, R.J.; Kim, R.S.; St Clair, M; Kuritzkes, D.R.; Kessler, H.; Fox, L.; Blanchard-Vargas, M.; Landay A.; for the AIDS Clinical Trials Group Protocol 375 Team. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS, 2002, 16, 1859-1866.
16. Grinspoon, S.; Carr, A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med., 2005, 352, 48-62.
17. Sudano, I.; Spieker, L.E.; Noll, G.; Corti, R.; Weber, R.; Lüscher, T.F. Cardiovascular disease in HIV infection. Am. Heart J., 2006, 151, 1147-55.
18. Triant, V.A.; Lee, H.; Hadigan, C.; Grinspoon, S.K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab., 2007, 92, 2506-2512.
19. Périard, D.; Telenti, A.; Sudre, P.M.; Cheseaux, J. J,; Halfon, P.; Reymond, M.J.; Marcovina, S.M.; Glauser, M.P.; Nicod, P.; Darioli, R.; Mooser, V. Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors. Circulation, 1999, 100, 700-707.
20. Fichtenbaum, C.J.; Gerber, J.G.; Rosenkranz, S.L.; Segal, Y.; Aberg, J.A.; Blaschke, T.; Alston, B.; Fang, F.; Kosel, B.; Aweeka, F. NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047, NIAID AIDS Clinical Trials Group. AIDS, 2002, 16, 569-577.
21. Monsuez, J.J.; Charniot, J.C.; Escaut, L.; Teicher, E.; Wyplosz, B.; Couzigou, C.; Vignat, N.; Vittecoq, D. Tumor necrosis factoralpha, interleukin-1, interleukin-6, interleukin-10, monocyte chemoattractant protein HIV-associated vascular diseases: structural and functional changes, clinical implications. Int. J. Cardiol., 2009, 133, 293-306.
22. de Gaetano Donati, K.; Rabagliati, R.; Iacoviello, L.; Cauda, R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect. Dis., 2004, 4, 213-222.
23. Mondy, K.E. Determinants of endothelial function in human immunodeficiency virus infection: a complex interplay among therapy, disease, and host factors. J. Cardiometab. Syndr., 2008, 3, 88-92.
24. Zandman-Goddard, G.; Shoenfeld, Y. HIV and autoimmunity. Autoimmun Rev., 2002, 1, 329-337.
25. Karmochkine, M.; Ankri, A.; Calvez, V.; Bonmarchant, M.; Coutellier, A.; Herson, S. Plasma hypercoagulability is correlated to plasma HIV load. Thromb Haemost., 1998, 80, 208-209.
26. Baker, J.V.; Peng, G.; Rapkin, J.; Abrams, D.I.; Silverberg, M.J.; MacArthur, R.D.; Cavert, W.P.; Henry, W.K.; Neaton, J.D. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS, 2008, 22, 841-848.
27. Marin, B.; Thiébaut, R.; Bucher, H.C.; Rondeau, V.; Costagliola, D.; Dorrucci, M.; Hamouda, O.; Prins, M.; Walker, S.; Porter, K.; Sabin, C.; Chêne, G. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS, 2009, 23, 1743-1753.
28. Phillips, A.N.; Neaton, J.; Lundgren, J.D. The role of HIV in serious diseases other than AIDS. AIDS, 2008, 22, 2409-2418.
29. Paton, P.; Tabib, A.; Loire, R.; Tete, R. Coronary artery lesions and human immunodeficiency virus infection. Res. Virol., 1993, 144, 225-231.
30. Tabib, A.; Greenland, T.; Mercier, I.; Loire, R.; Mornex, J.F. Coronary lesions in young HIV positive patients at necroscopy. Lancet, 1992, 340, 1039-1040.
31. Tabib, A.; Leroux, C.; Mornex, J.F.; Loire, R. Accelerated coronary atherosclerosis and arteriosclerosis in young humanimmunodeficiency-virus-positive patients. Coron. Artery Dis., 2000, 11, 41-46.
32. Micheletti, R.G.; Fishbein, G.A.; Fishbein, M.C.; Singer, E.J.; Weiss, R.E.; Jeffries, R.A.; Currier, J.S. Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: a histopathologic study. Cardiovasc. Pathol., 2009, 18, 28-36.
33. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr, W.M.; Lundgren, J.D.; Neaton, J.D.; Gordin, F.; Abrams, D.; Arduino, R.C.; Babiker, A.; Burman, W.; Clumeck, N.; Cohen, C.J.; Cohn, D.; Cooper, D.; Darbyshire, J.; Emery, S.; Fätkenheuer, G.; Gazzard, B.; Grund, B.; Hoy, J.; Klingman, K.; Losso, M.; Markowitz, N.; Neuhaus, J.; Phillips, A.; Rappoport, C. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med., 2006, 355, 2283-2296.
34. Hsue, P.Y.; Lon, J.C.; Franklin, A.; Lo, J.C.; Franklin, A.; Bolger, A.F.; Martin, J.N.; Deeks, S.G.; Waters, D.D. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation, 2004, 109, 1603-1609.
35. van Vonderen, M.G.; Smulders, Y.M.; Stehouwer, C.D.; Danner, S.A.; Gundy, C.M.; Vos, F.; Reiss, P.; Agtmael, M.A. Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J. Acquir. Immune. Defic. Syndr., 2009, 50, 153-161.
36. Hsue, P.Y.; Hunt, P.W.; Sinclair, E.; Bredt, B.; Franklin, A.; Killian, M.; Hoh, R.; Martin, J.N.; McCune, J.M.; Waters, D.D.; Deeks, SG. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS, 2006, 20, 2275-2283.
37. Calmy, A.; Gayet-Ageron, A.; Montecucco, F.; Nguyen, A.; Mach, F.; Burger, F.; Ubolyam, S.; Carr, A.; Ruxungtham, K.; Hirschel, B; Ananworanich, J.; STACCATO Study Group. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS, 2009, 23, 929-39.
38. Kitahata, M.M.; Gange, S.J.; Abraham, A.G.; Gange, S.J.; Abraham, A.; Merriman, B.; Saag, M.S.; Justice, A.C.; Hogg, R.S.; Deeks, S.G.; Eron, J.J.; Brooks, J.T.; Rourke, S.B.; Gill, M.J.; Bosch, R.J.; Martin, J.N.; Klein, M.B.; Jacobson, L.P.; Rodriguez, B.; Sterling, T.R.; Kirk, G.D.; Napravnik, S.; Rachlis, A.R.; Calzavara, L.M.; Horberg, M.A.; Silverberg, M.J.; Gebo, K.A.; Goedert, J.J.; Benson, C.A.; Collier, A.C.; Van Rompaey, S.E.; Crane, H.M.; McKaig, R.G.; Lau, B.; Freeman, A.M.; Moore, R.D.; NAACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med., 2009, 360, 1815-26.
39. Gallant, J.E.; Staszewski, S.; Pozniak, A.L.; DeJesus, E.; Suleiman, J.M.; Miller, M.D.; Coakley, D.F.; Lu, B.; Toole, J.J.; Cheng, A.K.; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA, 2004, 292, 191-201.
40. Gulick, R.M.; Meibohm, A.; Havlir, D.; Eron, J.J.; Mosley, A.; Chodakewitz, J.A.; Isaacs, R.; Gonzalez, C.; McMahon, D.; Richman, D.D.; Robertson, M.; Mellors, J.W. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS, 2003, 17, 2345-2349.
41. Hicks, C.; King, M.S.; Gulick, R.M.; White, A.C. Jr.; Eron, J.J. Jr.; Kessler, H.A.; Benson, C.; King, K.R.; Murphy, R.L.; Brun, S.C. Long-term safety and durable antiretroviral activity of lopinavir/ ritonavir in treatment-naive patients: 4 year follow-up study. AIDS, 2004, 18, 775-779.
42. Murphy, R.L.; da Silva, B.A.; Hicks, C.B.; Eron, J.J.; Gulick, R.M.; Thompson, M.A.; McMillan, F.; King, M.S.; Hanna, G.J.; Brun, S.C. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin. Trials. 2008, 9, 1-10.
43. Willig, J.H.; Abroms, S.; Westfall, A.O.; Routman, J.; Adusumilli, S.; Varshney, M.; Allison, J.; Chatham, A.; Raper, J.L.; Kaslow, R.A.; Saag, M.S.; Mugavero, M.J. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS, 2008, 22, 1951-1960.
44. Elzi, L.; Marzolini, C.; Furrer, H.; Ledergerber, B.; Cavassini, M.; Hirschel, B.; Vernazza, P.; Bernasconi, E.; Weber, R.; Battegay, M. Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch. Intern. Med., 2010, 170, 57-65.
45. Torriani, F.; Komarow, L.; Parker, R.A.; Cotter, B.R.; Currier, J.S.; Dubé, M.P.; Fichtenbaum, C.J.; Gerschenson, M.; Mitchell, C.K.; Murphy, R.L.; Squires, K.; Stein, J.H.; ACTG 5152s Study Team. Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy The ACTG (AIDS Clinical Trials Group) Study 5152s. J. Am. Coll Cardil., 2008, 52, 569-576.
46. Corrado, E.; Rizzo, M.; Coppola, G.; Fattouch, K.; Novo, G.; Marturana, I.; Ferrara, F.; Novo, S. An update on the role of markers of inflammation in atherosclerosis. J. Atheroscler Thromb., 2010, 17, 1-11.
47. Bozzette, S.A.; Ake, C.F.; Tam, H.K.; Chang, S.W.; Louis, T.A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med., 2003, 348, 702-710.
48. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med., 2003, 349, 1993-2003.
49. Monsuez, J.J.; Charniot, J.C.; Escaut, L.; Teicher, E.; Wyplosz, B.; Couzigou, C.; Vignat, N.; Vittecoq, D. HIV-associated vascular diseases: structural and functional changes, clinical implications. Int. J. Cardiol., 2009, 133, 293-306.
50. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med., 2007, 356, 1723-1735.
51. Dressman, J.; Kincer, J.; Matveev, S.V.; Guo, L.; Greenberg, R.N.; Guerin, T.; Meade, D.; Li, XA.; Zhu, W.; Uittenbogaard, A.; Wilson, M.E.; Smart, E.J. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J. Clin. Invest., 2003, 111, 389-397.
52. Stein, J.H.; Klein, M.A.; Bellehumeur, J.L.; McBride, P.E.; Wiebe, D.A.; Otvos, J.D.; Sosman, J.M. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation, 2001, 104, 257-62.
53. Mallon, P.; Sattar, N. Cardiovascular Risk in the HIV-infected patient. Eur. Infect. Dis., 2008, 2, 12-19.
54. Seminari, E.; Pan, A.; Voltini, G.; Carnevale, G.; Maserati, R.; Minoli, L.; Meneghetti, G.; Tinelli, C.; Testa, S. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIVpositive patients treated with protease inhibitors. Atherosclerosis, 2002, 162, 433-438.
55. Chironi, G.; Escaut, L.; Gariepy, J.; Cogny, A.; Teicher, E.; Monsuez, J.J.; Levenson, J.; Simon, A.; Vittecoq, D. Brief report: carotid intimamedia thickness in heavily pretreated HIV-infected patients. J. Acquir. Immune. Defic. Syndr., 2003, 32, 490-493.
56. Meng, Q.; Lima, J.A.; Lai, H.; Vlahov, D.; Celentano, D.D.; Strathdee, S.A.; Nelson, K.E.; Wu, K.C.; Chen, S.; Tong, W.; Lai, S. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am. Heart. J., 2002, 144, 642-648.
57. Flammer, A.J.; Vo, N.T.; Ledergerber, B.; Hermann, F.; Gämperli, A.; Huttner, A.; Evison, J.; Baumgartner, I.; Cavassini, M.; Hayoz, D.; Quitzau, K.; Hersberger, M.; Sudano, I.; Ruschitzka, F.; Lüscher, T.F.; Noll, G.; Weber, R. Endothelial function: Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomized controlled trial. Heart, 2009, 95, 385-390.
58. D:A:D Study Group: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, 2008, 371, 1417-1426.
59. Strategies for Management of Antiretroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS, 2008, 22, F17-F24.
60. Hsue, P.Y.; Hunt, P.W.; Wu, Y.; Schnell, A.; Ho, J.E.; Hatano, H.; Xie, Y.; Martin, J.N.; Ganz, P.; Deeks, S.G. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS, 2009, 23, 2021-2027.
61. Parker, W.B.; Shaddix, S.C.; Bowdon, B.J.; Rose, L.M.; Vince, R.; Shannon, W.M.; Bennett, L.L. Jr. Metabolism of carbovir: a potent inhibitor of human immunodeficiency virus type 1, and its effect on cellular metabolism. Antimicrob. Agents Chemother., 1993, 37, 1004-1009.
62. Hammond, E.; McKinnon, E.; Mallal, S.; Nolan, D. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS, 2008, 22, 2540-2543.
63. th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 19-22, 2009.
64. Nolan, D.; Watts, G.F.; Herrmann, S.E.; French, M.A.; John, M.; Mallal, S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM, 2003, 96, 825-832.
65. Lichtner, M.; Cuomo, M.R.; Rossi, R.; Strano, S.; Massetti, A.P.; Mastroianni, C.M.; Vullo, V. Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment. Atherosclerosis, 2009, 204: e1-e3.
66. Fontas, E.; Van Leth, F.; Sabin, C.A.; Friis-Møller, N.; Rickenbach, M.; d'Arminio Monforte, A.; Kirk, O.; Dupon, M.; Morfeldt, L.; Mateu, S.; Petoumenos, K.; El-Sadr, W.; de Wit, S.; Lundgren, J.D.; Pradier, C.; Reiss, P.; D:A:D Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associate with different lipid profiles? J. Infect. Dis., 2004, 189, 1056-1074.